Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
作者： Beata Holkova , Maciej Kmieciak , Prithviraj Bose , Victor Y. Yazbeck , Paul M. Barr
DOI: 10.3109/10428194.2015.1075019
关键词:
摘要: A phase 1 study with carfilzomib and vorinostat was conducted in 20 B-cell lymphoma patients. Vorinostat given orally twice daily on days 1, 2, 3, 8, 9, 10, 15, 16, 17 followed by (given as a 30-min infusion) 16. treatment cycle 28 days. Dose escalation initially standard 3 + 3 design, but adapted more conservative accrual rule following dose de-escalation. The maximum tolerated 20 mg/m2 100 mg (twice daily). dose-limiting toxicities were grade 3 pneumonitis, hyponatremia, febrile neutropenia. One patient had partial response two patients stable disease. Correlative studies showed decrease NF-κB activation an increase Bim levels some patients, these changes did not correlate clinical response.
sci-hub.se 参考文章(45)
Mamta Gupta, Jing Jing Han, Mary Stenson, Matthew Maurer, Linda Wellik, Guangzhen Hu, Steve Ziesmer, Ahmet Dogan, Thomas E. Witzig, Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood. ,vol. 119, pp. 2844- 2853 ,(2012) , 10.1182/BLOOD-2011-10-388538
Girija Dasmahapatra, Dmitry Lembersky, Lora Kramer, Richard I. Fisher, Jonathan Friedberg, Paul Dent, Steven Grant, The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo Blood. ,vol. 115, pp. 4478- 4487 ,(2010) , 10.1182/BLOOD-2009-12-257261
James O Armitage, Randy D Gascoyne, Matthew A Lunning, Franco Cavalli, Non-Hodgkin lymphoma The Lancet. ,vol. 390, pp. 298- 310 ,(2003) , 10.1016/S0140-6736(16)32407-2
Takashi Watanabe, Harumi Kato, Yukio Kobayashi, Satoshi Yamasaki, Yuriko Morita-Hoshi, Hiroki Yokoyama, Yasuo Morishima, Justin L. Ricker, Tetsuya Otsuki, Akiko Miyagi-Maesima, Yoshihiro Matsuno, Kensei Tobinai, Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Science. ,vol. 101, pp. 196- 200 ,(2010) , 10.1111/J.1349-7006.2009.01360.X
Georg Hopfinger, Thomas Nösslinger, Alois Lang, Werner Linkesch, Thomas Melchardt, Lukas Weiss, Alexander Egle, Richard Greil, Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Annals of Hematology. ,vol. 93, pp. 459- 462 ,(2014) , 10.1007/S00277-014-2009-0
W S Xu, R B Parmigiani, P A Marks, Histone deacetylase inhibitors: molecular mechanisms of action Oncogene. ,vol. 26, pp. 5541- 5552 ,(2007) , 10.1038/SJ.ONC.1210620
Madeleine Duvic, Rakshandra Talpur, Xiao Ni, Chunlei Zhang, Parul Hazarika, Cecilia Kelly, Judy H. Chiao, John F. Reilly, Justin L. Ricker, Victoria M. Richon, Stanley R. Frankel, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood. ,vol. 109, pp. 31- 39 ,(2007) , 10.1182/BLOOD-2006-06-025999
Anas Younes, Beyond chemotherapy: new agents for targeted treatment of lymphoma Nature Reviews Clinical Oncology. ,vol. 8, pp. 85- 96 ,(2011) , 10.1038/NRCLINONC.2010.189
Ahmed Sawas, Catherine Diefenbach, Owen A OʼConnor, New therapeutic targets and drugs in non-Hodgkin's lymphoma Current Opinion in Hematology. ,vol. 18, pp. 280- 287 ,(2011) , 10.1097/MOH.0B013E328347786D
Rebecca Siegel, Carol DeSantis, Katherine Virgo, Kevin Stein, Angela Mariotto, Tenbroeck Smith, Dexter Cooper, Ted Gansler, Catherine Lerro, Stacey Fedewa, Chunchieh Lin, Corinne Leach, Rachel Spillers Cannady, Hyunsoon Cho, Steve Scoppa, Mark Hachey, Rebecca Kirch, Ahmedin Jemal, Elizabeth Ward, Cancer treatment and survivorship statistics, 2012 CA: A Cancer Journal for Clinicians. ,vol. 62, pp. 220- 241 ,(2012) , 10.3322/CAAC.21149